POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

Clinical trials for POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.

Never miss a new study

Get alerted when new POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear

Sign up with your email to follow new studies for POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 8 Not yet recruiting 1 Not yet finished but already full! 2 Terminated 2

New drug duo targets Tough-to-Treat blood cancer

Disease control Not yet recruiting

This study is testing whether a combination of two drugs, pacritinib and selinexor, can help control myelofibrosis in patients who have not yet tried a common type of treatment (JAK inhibitors) and who have low red blood cell and platelet counts. The main goals are to see if the …

Matched conditions: POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

Get alerted when new POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear

New drug duo targets Tough-to-Treat blood cancer